A study reported at IDWeek 2012 comparing the efficacy of different statins when co-administered with highly active antiretroviral therapy in patients with HIV found no significant difference in LDL reduction.
Two doses of the investigational hepatitis B vaccine, HEPLISAV, induced significantly earlier and higher rates of seroprotection than Engerix-B, according to study results at IDWeek 2012.
A study of patients with chronic hepatitis C and a history of hepatocellular carcinoma treated with pegylated interferon alpha-2b plus ribavirin showed a high risk of recurrence, according to data presented at IDWeek 2012.
Patients who received an entirely acellular pertussis vaccine series had a “markedly increased risk of disease” compared with those receiving even 1 dose of whole-cell pertussis vaccine, investigators reported during IDWeek 2012.
A pre-admission protocol using cutaneous chlorhexidine gluconate cloths significantly reduced the incidence of surgical site infections vs in-hospital peri-operative skin preparation only, according to a study presented IDWeek 2012.
The antiretroviral combination known as “the Quad” demonstrated comparable efficacy and favorable tolerability to Atripla in adherent treatment-naïve patients with HIV infection, according to a a study presented at IDWeek 2012.
Oral delafloxacin is effective against ABECB and for community-acquired pneumonia, according to results of two double-blind randomized phase 2 trials presented at IDWeek2012.
Carbapenem-resistant gram-negative bactierial infections are strongly associated with previous antibiotic use and health care exposure, according to study results presented at IDWeek 2012.
A post-hoc analysis of data pooled from the largest multicenter, randomized, double-blinded, head-to-head clinical trials to date involving patients with Clostridium difficile-associated diarrhea treated with oral vancomycin and oral metronidazole presented at IDWeek 2012 has shown statistically superior clinical success with oral vancomycin.
David A. Kaufman, MD, from the University of Virginia, presented study findings at IDWeek 2012 that showed targeted prophylaxis of fluconazole in infants <1,000g or ≤27 weeks using a 3mg/kg twice-weekly dose with a different antifungal used for treatment is effective in preventing invasive Candida infections.
Want to read more?
Please login or register first to view this content.